Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 1:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 279 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Arginine-hydrochloride Clear all
Active, not recruiting Phase 1 Interventional

The Effects of ATLAS Therapy on Nitric Oxide Bioavailability in Patients With Intermittent Claudication

NCT04800692
View directory record Official record
Conditions
Claudication, Intermittent, Peripheral Artery Disease, Peripheral Vascular Diseases
Interventions
Tetrahydrobiopterin 10 mg/kg, Tetrahydrobiopterin 20 mg/kg, L-Ascorbate, L-Arginine
Drug
Lead sponsor
Louis Messina
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 9, 2026, 1:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Examine the Effect of a Thermogenic Energy Drink in Healthy Adults

NCT05061797
View directory record Official record
Conditions
Metabolism
Interventions
Thermogenic Energy Drink - Active Study Product Formula, Placebo
Dietary Supplement
Lead sponsor
Rowdy Energy
Industry
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Oct 9, 2026, 1:30 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Objective of This Study Was to Compare and Quantify the Bioavailability of Citrulline Byproducts in Blood Samples and in Urine Samples After a Single Dose of the Assigned Dietary Supplement. The Treatment Arms Containing the Following Molecules: Citrulline HCL and L-Citrulline,

NCT06977854
View directory record Official record
Conditions
Bioavailability and AUC
Interventions
Removal from study. In case of adverse event, subject treated for the AE., removal from study
Other
Lead sponsor
Vireo Systems, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Raritan, New Jersey
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 9, 2026, 1:30 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Intranasal Vasopressin Treatment in Children With Autism

NCT03204786
View directory record Official record
Conditions
Autism, Autism Spectrum Disorder, ASD
Interventions
Vasopressin (USP) Injectable Solution [Vasostrict], Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
6 Years to 17 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 9, 2026, 1:30 AM EDT
Terminated Phase 1 Interventional

Effect of an Oral Supplement Enriched in Amino Acids and the Leucine Metabolite B-hydroxy B-methylbutyrate (HMB)

NCT00502372
View directory record Official record
Conditions
Pressure Ulcers
Interventions
Nutritional Supplement/Amino acids and HMB, Juven
Dietary Supplement
Lead sponsor
Central Arkansas Veterans Healthcare System
Federal
Eligibility
21 Years to 90 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 15, 2015 · Synced Oct 9, 2026, 1:30 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)

NCT06085729
View directory record Official record
Conditions
Prostate Cancer
Interventions
ADI-PEG 20, Cabazitaxel, Carboplatin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 9, 2026, 1:30 AM EDT
Completed Phase 2 Interventional

Phase II Study of Arginine Butyrate With or Without Epoetin Alfa in Patients With Thalassemia Intermedia

NCT00006136
View directory record Official record
Conditions
Beta-Thalassemia
Interventions
arginine butyrate, epoetin alfa
Drug
Lead sponsor
Boston University
Other
Eligibility
3 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
6
States / cities
Oakland, California • New Haven, Connecticut • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2005 · Synced Oct 9, 2026, 1:30 AM EDT
Completed Phase 1 Interventional

Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer

NCT02101593
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
ADI-PEG 20
Drug
Lead sponsor
Polaris Group
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
New York, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 4, 2016 · Synced Oct 9, 2026, 1:30 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Vascular and Metabolic Effects of Hormone Therapy Combined With L-Arginine in Postmenopausal Women

NCT00001752
View directory record Official record
Conditions
Hypercholesterolemia, Postmenopause
Interventions
L-arginine, Estrogen
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 9, 2026, 1:30 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Effects of Resveratrol Supplements on Vascular Health in Postmenopausal Women

NCT01564381
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
ResA, Resveratrol, Placebo
Dietary Supplement
Lead sponsor
University of California, Davis
Other
Eligibility
50 Years to 70 Years · Female only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2017 · Synced Oct 9, 2026, 1:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Mechanisms of Cerebrovascular Control

NCT02936687
View directory record Official record
Conditions
Metabolic Syndrome X
Interventions
NOS Inhibition, ET-1 Inhibition, NOS Inhibition Placebo, 3 Tesla MRI, Intravenous Catheter, Oral Glucose Tolerance Test, ET-1 Inhibition Placebo
Drug · Device · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 45 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Oct 9, 2026, 1:30 AM EDT
Completed Not applicable Interventional

L-arginine for Prevention of Kidney Damage in Liver Transplant Recipients

NCT00587418
View directory record Official record
Conditions
Liver Transplant Recipients
Interventions
L-arginine, Placebo
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 9, 2026, 1:30 AM EDT
Completed Phase 2 Interventional Results available

Study of the Effect of Intradialytic Vasopressin on Chronic Hypertension in Patients With End Stage Renal Disease

NCT01247090
View directory record Official record
Conditions
Hypertension, End Stage Renal Disease
Interventions
Vasopressin - Very Low Dose, Vasopressin - Low Dose, Placebo Comparator
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 9, 2026, 1:30 AM EDT
Completed Phase 3 Interventional Results available

Perindopril Amlodipine for the Treatment of Hypertension

NCT01556997
View directory record Official record
Conditions
Essential Hypertension
Interventions
XOMA 985, Amlodipine Besylate, Perindopril Erbumine
Drug
Lead sponsor
Symplmed Pharmaceuticals LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
837 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
48
States / cities
Huntsville, Alabama • Muscle Shoals, Alabama • Glendale, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Oct 9, 2026, 1:30 AM EDT
Suspended Phase 1Phase 2 Interventional

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

NCT04278768
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions
Emavusertib, Venetoclax
Drug
Lead sponsor
Curis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
12
States / cities
Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 9, 2026, 1:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Clinical Study to Assess the Gingivitis and Plaque Effects of Various Dentifrices

NCT06140784
View directory record Official record
Conditions
Gingivitis
Interventions
0.76% Sodium Monofluorophosphate Dentifrice, 0.454% Stannous Fluoride Dentifrice
Drug
Lead sponsor
Procter and Gamble
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Whittier, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2024 · Synced Oct 9, 2026, 1:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Local Antioxidant Therapy Vasoconstriction Effects in Different Races

NCT03684213
View directory record Official record
Conditions
Cardiovascular Diseases, Cardiovascular Risk Factor, Vasoconstriction
Interventions
Control (Norepinephrine), Norepinephrine + Ascorbic Acid, Norepinephrine + L-NAME, Norepinephrine + L-NAME + Ascorbic Acid
Drug
Lead sponsor
The University of Texas at Arlington
Other
Eligibility
18 Years to 35 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Oct 9, 2026, 1:30 AM EDT
Completed Phase 1 Interventional

Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer

NCT02101580
View directory record Official record
Conditions
Advanced Pancreatic Cancer
Interventions
ADI-PEG 20
Drug
Lead sponsor
Polaris Group
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2020 · Synced Oct 9, 2026, 1:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Dietary Amino Acid Profile on Lipoprotein Metabolism, Vascular Reactivity and Inflammatory Markers

NCT00175084
View directory record Official record
Conditions
Hyperlipidemias, Metabolic Syndrome X, Cardiovascular Diseases
Interventions
Comparison of dietary protein amino acid profile
Behavioral
Lead sponsor
Tufts University
Other
Eligibility
50 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 23, 2014 · Synced Oct 9, 2026, 1:30 AM EDT
Completed Phase 2 Interventional Results available

A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults

NCT03201419
View directory record Official record
Conditions
Nocturia
Interventions
FE 201836, Desmopressin, Placebo oral solution, Placebo ODT
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
43
States / cities
Birmingham, Alabama • Mobile, Alabama • Lincoln, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 9, 2026, 1:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Estradiol and Progesterone on Arginine Vasopressin Regulation and Serum Sodium Concentration

NCT00589134
View directory record Official record
Conditions
Exercise Induced Hyponatremia
Interventions
Gatorade Endurance Formula, ganirelix acetate
Dietary Supplement · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Oct 9, 2026, 1:30 AM EDT
Completed Phase 1 Interventional

Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma

NCT01665183
View directory record Official record
Conditions
Cutaneous Melanoma, Uveal Melanoma, Ovarian Carcinoma or Other Advanced Solid Tumors
Interventions
ADI-PEG 20
Drug
Lead sponsor
Polaris Group
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2016 · Synced Oct 9, 2026, 1:30 AM EDT
Recruiting Phase 1Phase 2 Interventional

RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma

NCT07150806
View directory record Official record
Conditions
Recurrent Meningioma
Interventions
Actinium Ac 225 DOTATATE RYZ101, Biospecimen Collection, Computed Tomography, Echocardiography Test, Gallium Ga 68-DOTATATE, L-lysine/L-arginine-containing Amino Acid, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography, Somatostatin Receptor Positron Emission Tomography
Drug · Procedure · Radiation
Lead sponsor
Joshua Palmer
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 9, 2026, 1:30 AM EDT
Recruiting Not applicable Interventional

DDAVP for Pituitary Adenoma

NCT04569591
View directory record Official record
Conditions
Cushing's Disease, Pituitary Adenoma
Interventions
Desmopressin acetate
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
8 Years to 99 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 9, 2026, 1:30 AM EDT